Mounjaro®
Starting from £179.99/mo
Start journey Learn moreFor most people, appetite begins to return within one to four weeks of stopping Wegovy. Hunger typically comes back gradually as semaglutide clears your system, and for many it feels noticeably stronger than before treatment — a pattern seen clearly in clinical trial follow-up data. Wegovy is a prescription-only medicine; any decision about stopping should be made with the clinician who prescribed it, not taken unilaterally.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Picture the last Wegovy pen sitting in the fridge door, used. The week after your final injection, semaglutide is still circulating at a meaningful level. The medicine's half-life is around seven days, which means concentrations halve each week. By week three or four, the pharmacological signal telling your brain you're full has faded substantially. By week five, most people have negligible levels left.
That timeline matters because appetite suppression tracks drug levels quite closely. The GLP-1 receptors that Wegovy activates (slowing gastric emptying, reducing hunger signals from the gut to the brain) stop receiving the same stimulus as blood concentration drops. Hunger doesn't crash back overnight. It creeps. You may notice it first as a return of interest in food between meals, then as stronger cravings, then as the familiar pre-treatment appetite.
For a fuller picture of how quickly the clearance process unfolds, the page on how long semaglutide stays in your system after stopping walks through the pharmacokinetics in detail. If you're also wondering how long it takes for Wegovy to curb appetite in the first place, that page gives useful context for understanding what you stand to lose when the drug clears. The short version: if your appetite felt reliably controlled at week eight of treatment, expect that control to begin loosening somewhere around weeks two to three post-stop, with the full effect gone by week five or six.
The NHS's patient information for semaglutide notes that the medicine should be used alongside a reduced-calorie diet and increased physical activity, and that the NHS medicines page for semaglutide covers what to expect during and after treatment, worth reading before making any decision to stop.
This is the part that surprises people most, and it's worth being direct about it. Clinical follow-up from the STEP 1 trial (the 68-week semaglutide study published in the New England Journal of Medicine) tracked participants for a year after treatment ended. Weight regain was substantial, and the mechanism was largely hunger: not just the return of baseline appetite, but in many cases a rebound that felt more intense.
There are plausible biological reasons for this. Adipose tissue and the gut communicate with the brain through hormones including leptin and ghrelin. When significant weight is lost, the body adjusts these signals in ways that increase hunger and reduce the sense of fullness, a response sometimes described as metabolic adaptation. Semaglutide suppresses these signals during treatment. When it's removed, those adaptations are still in place, which can leave hunger feeling louder than the pre-treatment baseline.
This isn't a reason to avoid stopping, it's a reason to plan the transition carefully, ideally with your prescriber. The question of how quickly weight tends to return after stopping semaglutide is explored separately, but the short answer is: quickly enough that stopping without a plan is rarely advisable.
A measured, gradual reduction in dose rather than an abrupt stop is one approach some clinicians use; whether that's appropriate for you is a clinical call. Habits built during treatment (protein-led meals, regular eating patterns, consistent movement) do meaningfully blunt the appetite rebound for people who've embedded them.
A common situation: someone runs out of Wegovy, faces a supply gap, or takes a planned break for surgery. A short interruption of one to two weeks is different from permanent discontinuation, though the appetite signal will still tick back up during any gap. Wegovy's overview page explains what the medicine is licensed for and how the treatment pathway works, useful context if you're weighing up whether to pause or stop altogether.
For people who've been on a lower dose and are considering stopping rather than titrating up, the question is partly about what the medicine was doing at that dose. If you want a clearer sense of how long Wegovy takes to reduce appetite at different stages, that page breaks down what to expect across the titration schedule. If you were well-controlled at 2.4mg maintenance, the contrast will be more noticeable.
Anyone considering stopping should tell their prescribing team rather than simply stopping ordering. A clinician who knows your history can help distinguish between a temporary break and a planned end of treatment, and can advise on managing the transition. Our prescribers handle exactly these conversations, if you're a current patient, the support team can connect you with aftercare. If you're exploring treatment options for the first time, the weight loss overview explains what's available and how the clinical process works.
Thinking about whether Wegovy might be appropriate again, or whether a different treatment fits better now? You can read Wegovy testimonials and before and after accounts from real patients to get a sense of how others have found the experience, then check your eligibility with our free consultation, a GPhC-registered prescriber reviews every application the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.